# Syncona Limited Make $80.0 million commitment to Freeline

- Link: https://www.directorstalkinterviews.com/syncona-limited-make-80-0-million-commitment-to-freeline/412801398
- Published: 2019-12-19T07:35:05+00:00
- Author: Giles Arbor

**Syncona Ltd** (LON: SYNC), a leading healthcare company focused on founding, building
and funding global leaders in life science, today announced that it has made a $
80.0 million commitment in a Series C financing by Freeline. Syncona has funded 
the first tranche of this commitment, amounting to $40.0 million (£30.6 million)[
3]. Syncona has a 79 per cent fully diluted ownership stake at the point full current
commitments are invested.

· $80.0 million (£61.1 million)[1] commitment to Freeline in a Series C financing,
a leading gene therapy company focused on liver expression for a range of chronic
systemic diseases

· Freeline has a pipeline of four disclosed programmes, two of which are clinical
stage, and is developing a next-generation gene therapy using a proprietary, novel
capsid and best-in-class manufacturing platform

· Freeline is valued at cost[2] and held at £149.1 million following the first tranche
of $40.0 million (£30.6 million) of the Series C investment

Freeline is progressing FLT180a, its lead programme in Haemophilia B, through clinical
development. The company has reported that the first two patients in its ongoing
Phase 1/2 trial who were treated with the lowest dose[4] have shown that Factor 
IX (FIX) activity remains stable and consistent at 40.5±4.5% through weeks 66 and
74 post administration. The normal range of FIX activity in the general population’s
blood is between 50 per cent and 150 per cent. Freeline uses a novel capsid which
is capable of driving high protein expression. The company continues to enrol Haemophilia
B patients as part of its dose-ranging trial. Freeline is currently seeking to identify
the optimal dosing regimen to deliver FIX activity consistently in the normal range
for all patients and will report further data in this financial year (by March 2020).

Freeline has also recently dosed the first patient in its second programme in Fabry
Disease, which it is estimated affects one in every 40,000[5] people. This programme
is the first clinical stage AAV gene therapy study targeting Fabry Disease globally.
The company also has disclosed pre-clinical programmes targeting Gaucher Disease
and Haemophilia A, which are part of a broad pipeline of systemic disorders, where
high protein expression is crucial to providing functional cures for patients.

Syncona’s first tranche of $40.0 million will enable the company to expand its team,
continue to develop its robust manufacturing platform including commercial supply
capability, generate further data in its clinical programmes for Haemophilia B and
Fabry Disease and continue to progress its pipeline.

**Chris Hollowood, Chief Investment Officer of Syncona ltd and Executive Chairman
of Freeline, said: **

“Freeline has developed a high-quality gene therapy platform with a novel capsid
capable of driving high expression levels to treat systemic diseases. We are encouraged
by the potential product profile in our lead programme in Haemophilia B and believe
Freeline has the opportunity to achieve functional cures for patients across a broad
pipeline of systemic diseases. We are continuing with dose optimisation and remain
on track to provide a clinical data update by financial year end.

“This financing demonstrates Syncona’s differentiated approach of funding our companies
over the long term. Our deep capital base enables us to continue to strongly back
our companies as they progress through the development cycle and navigate clinical
and operational risks. We look forward to continuing to work in close partnership
with Freeline.”

In line with Syncona’s valuation policy, we continue to hold our investment in Freeline
at cost[6] until material clinical data is generated, or a third-party financing
or other factor occurs, that indicates that cost[7] is no longer the appropriate
measure of fair value.

[1] As at exchange rate on 18 December 2019

[2] For the purposes of fair value, cost is equivalent to calibrated cost

[3] See footnote 1

[4] The first cohort were treated at 4.5x1011vg/kg

[5] http://www.fabry.org/fsig.nsf/pages/fabry

[6] See footnote 3

[7] See footnote 3

Share on:
